Skip to main content

Phesgo FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 27, 2021.

FDA Approved: Yes (First approved June 29, 2020)
Brand name: Phesgo
Generic name: pertuzumab, trastuzumab, and hyaluronidase-zzxf
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Breast Cancer

Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a combination of two HER2/neu receptor antagonists and the endoglycosidase hyaluronidase indicated for the treatment of early and metastatic HER2-positive breast cancer, as detected by an FDA-approved companion diagnostic test.

Development timeline for Phesgo

Jun  3, 2023Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Jun 29, 2020Approval FDA Approves Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) for HER2-Positive Breast Cancer
Feb 24, 2020FDA Accepts Genentech’s Biologics License Application for Fixed-Dose Subcutaneous Combination of Perjeta And Herceptin For HER2-Positive Breast Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.